THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 118 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is 7.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345 | -51.0% | 40 | -41.2% | 0.00% | – |
| Q2 2023 | $704 | +70300.0% | 68 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 68 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 68 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -98.1% | 68 | -99.0% | 0.00% | – |
| Q3 2021 | $52,000 | -33.3% | 7,000 | +84.2% | 0.00% | – |
| Q1 2021 | $78,000 | +14.7% | 3,800 | 0.0% | 0.00% | – |
| Q4 2020 | $68,000 | +23.6% | 3,800 | +3.1% | 0.00% | – |
| Q3 2020 | $55,000 | +511.1% | 3,687 | +738.0% | 0.00% | – |
| Q2 2020 | $9,000 | -92.6% | 440 | -91.6% | 0.00% | -100.0% |
| Q1 2020 | $121,000 | -13.6% | 5,250 | -3.0% | 0.00% | 0.0% |
| Q4 2019 | $140,000 | -15.7% | 5,410 | -36.4% | 0.00% | 0.0% |
| Q3 2019 | $166,000 | -9.3% | 8,500 | -24.1% | 0.00% | -50.0% |
| Q2 2019 | $183,000 | -28.0% | 11,199 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $254,000 | – | 11,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Woodford Investment Management Ltd | 11,213,879 | $254,331,000 | 30.84% |
| Cormorant Asset Management, LP | 1,300,000 | $29,484,000 | 2.18% |
| Baupost Group | 9,309,168 | $211,132,000 | 1.85% |
| SENZAR ASSET MANAGEMENT, LLC | 27,397 | $621,000 | 1.79% |
| ARMISTICE CAPITAL, LLC | 1,180,000 | $26,762,000 | 1.75% |
| Old West Investment Management, LLC | 111,101 | $2,519,000 | 1.27% |
| Chescapmanager LLC | 403,321 | $9,147,000 | 1.06% |
| Virtus ETF Advisers LLC | 30,055 | $682,000 | 0.60% |
| Rock Springs Capital Management LP | 652,600 | $14,801,000 | 0.57% |
| Foundation Asset Management, LP | 27,154 | $616,000 | 0.53% |